The short version: we score each tirzepatide program from 0 to 10 across five criteria, weighted by how much each one affects a patient's safety, outcome, and total cost. Pricing transparency and pharmacy disclosure carry the most weight (25% each) because, for a medication that is compounded and not FDA-approved, what you pay and who makes your drug are the two facts that matter most. The same rubric is applied to every program; nothing about our affiliate relationship with MaxLife changes the math.
The five criteria and their weights
Each criterion below lists its weight and, in italics, the tirzepatide-specific question we are really answering.
- Pricing transparency — 25%. Is the tirzepatide price flat and all-in, or is it inflated by a separate membership fee, per-dose upcharges, or pricing gated behind an intake quiz? For tirzepatide specifically, we check whether the price holds as you titrate up to higher maintenance doses, since some programs charge more as your dose increases.
- Pharmacy disclosure — 25%. Does the program name its compounding pharmacy and can it supply a certificate of analysis for potency and sterility? Because compounded tirzepatide is not FDA-approved, the pharmacy is the single most important quality signal.
- Review score & volume — 20%. What are the verified ratings across Trustpilot, BBB, and app stores, and how many reviews sit behind them? We discount ratings that platforms have flagged for suspected incentivized or inauthentic reviews.
- Clinical oversight — 15%. Live video visits versus async questionnaires, dietitian access, and ongoing monitoring. For tirzepatide, we value programs that check in as you step up your dose, when side effects most often appear.
- Support & guarantee — 15%. Responsiveness, refund terms, and any results or money-back guarantee. We note guarantee conditions honestly, including adherence requirements, rather than treating a guarantee as a blanket promise.
Why pricing and pharmacy carry the most weight
These two criteria account for half the score by design. Tirzepatide is a compounded, non-FDA-approved medication when it is not the branded product, so the compounding pharmacy determines what is actually in the vial — making named, accredited pharmacies a genuine safety signal, not a marketing nicety. And because tirzepatide programs commonly cost between roughly $195 and $349 per month before discounts, opaque pricing (hidden membership fees, dose-based upcharges, quiz-gated prices) directly changes what a patient pays. A program that is honest and flat on both fronts is doing the two things that matter most for this drug.
How the tirzepatide lens changes scoring
The rubric is shared across our sister sites, but on this site we read it specifically for tirzepatide. That means: we weigh whether the flat price survives titration to higher maintenance doses; we treat oral tirzepatide formats cautiously because their bioavailability differs from injectable and is less studied; and we factor in tirzepatide-specific regulatory exposure, such as the confirmed Eli Lilly litigation over oral compounded tirzepatide, which is a documented fact for at least one ranked program. None of this is speculative — each factor maps to a sourced data point on the provider.
What efficacy numbers we cite — and how
When we mention weight-loss figures, they are clinical-trial averages for the FDA-approved branded drugs, not promises. Branded tirzepatide produced about 24.3% average weight loss in SURMOUNT-1 over 72 weeks with diet and exercise (Jastreboff et al., NEJM 2022); branded semaglutide produced about 15% in STEP 1 (Wilding et al., NEJM 2021). These are clinical-trial averages; individual results vary and are not guaranteed. We never present these as results you personally will achieve, and we never attach trial numbers to compounded products as if the trials studied them — they did not.
Where our data comes from
Program pricing, review counts, pharmacy disclosures, and regulatory facts are sourced from each provider's own site and from public records (Trustpilot, BBB, court dockets, FDA records) as of June 2026. Competitor pricing pages frequently block automated access and review counts move constantly, so we label competitor figures as sourced June 2026 and ask readers to verify live before deciding. Where we do not yet hold a confirmed value — for example, a program's exact guarantee terms or a pharmacy partner list — we show a visible {{placeholder}} rather than guess. We do not publish invented prices, reviews, patients, or providers.
Why this is a shortlist, not a top ten
The brand is Top 10 Tirzepatide, but we currently hold sourced, verifiable data for four compounded tirzepatide programs — so we rank four, honestly, rather than padding the list with programs we cannot stand behind. We separately cover branded Zepbound® routes as additional options. As we verify more programs against this rubric, we will add them.
Conflicts of interest
This site is published by Generation Health, LLC and earns referral commissions from providers we feature, including MaxLife, which is ranked #1. We disclose that on every page. MaxLife earns its position on measurable strengths — flat all-in tirzepatide pricing, named pharmacy partners, all-50-state coverage, a 4.4 Trustpilot score, and a clean regulatory record as of June 2026 — and we publish its real trade-offs, including a smaller review base than the national giants and the fact that its tirzepatide is compounded and not FDA-approved. We do not claim MaxLife is the only program with a clean record; TrimRx also has no lawsuit or FDA warning letter on record as of June 2026.
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine, 2021.
- Provider pricing, review, and regulatory figures: each provider's own website; Trustpilot; BBB; public court dockets; FDA records. Sourced June 2026.